A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMG 193 (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Amgen

Most Recent Events

25 Nov 2024 Planned End Date changed from 12 Sep 2029 to 19 Feb 2029.
25 Nov 2024 Planned primary completion date changed from 13 Sep 2027 to 20 Feb 2027.
15 Oct 2024 Planned initiation date changed from 23 Sep 2024 to 18 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight